Angiotensin II receptor antagonists – we have moved closer to the patient
Aim. To investigate antihypertensive efficacy of losartan (Lozap®), as monotherapy and in combination with a diuretic hydrochlorothiazide (Lozap® Plus), according to its influence on circadian blood pressure profile (CBPP) in patients with arterial hypertension (AH). Material and methods. In 25 pati...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/929 |
| _version_ | 1797882842704773120 |
|---|---|
| author | L. G. Ratova I. P. Kolos I. E. Chazova |
| author_facet | L. G. Ratova I. P. Kolos I. E. Chazova |
| author_sort | L. G. Ratova |
| collection | DOAJ |
| description | Aim. To investigate antihypertensive efficacy of losartan (Lozap®), as monotherapy and in combination with a diuretic hydrochlorothiazide (Lozap® Plus), according to its influence on circadian blood pressure profile (CBPP) in patients with arterial hypertension (AH). Material and methods. In 25 patients with Stage I-II AH, the influence of 8-week Lozap® monotherapy (n=12), 50 mg/d, and its fixed-dose combination with hydrochlorothiazide, Lozap® Plus (n=13), on CBPP was studied. Office BP (BPo) measurement, and 24-hour BP monitoring (BPM) were performed. Results. After 4 weeks of Lozap® monotherapy, BPo decreased by -8.4±10.7/-11.2±10.7 mm Hg (p<0.001); target BP level was reached in 48% of participants. By Week 8, BPo decreased by -13.0±9.0/-5.8±9.2 mm Hg (p<0.0001/0.01); target BP level was achieved in 92% of the patients. According to 24-hour BPM, daytime BP decreased by -22.3±12.1/13.8±11.2 mm Hg (р<0.0001), nighttime BP - by -25.9±16.7/16.4±11.3 mm Hg (р<0.0001). Daytime, nighttime, and 24-hour target BP levels were reached in 80%, 72%, and 88% of the participants, respectively. Т/Р ratio 71.6%/72.9% is an evidence of sufficient, even antihypertensive effect of Lozap® and Lozap® Plus. These medications significantly increased nighttime BP decline and normalized BP circadian rhythm (CP) in most patients. The therapy was well tolerated, with minimal adverse reactions, and side effects. Conclusion. Antihypertensive therapy with Lozap® and Lozap® Plus provides prolonged and even antihypertensive effect, corrects CBPP by reducing pressure workload, pulse BP, and improving BP CR. The maximal-dose therapy gives an opportunity to achieve target BP levels in 92% of the patients. |
| first_indexed | 2024-04-10T03:41:02Z |
| format | Article |
| id | doaj.art-dd529c0b48054611917485e17f623b25 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:41:02Z |
| publishDate | 2005-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-dd529c0b48054611917485e17f623b252023-03-13T07:23:11Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-04-01424045644Angiotensin II receptor antagonists – we have moved closer to the patientL. G. Ratova0I. P. Kolos1I. E. Chazova2Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса МЗ и СР РФ, МоскваИнститут клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса МЗ и СР РФ, МоскваИнститут клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса МЗ и СР РФ, МоскваAim. To investigate antihypertensive efficacy of losartan (Lozap®), as monotherapy and in combination with a diuretic hydrochlorothiazide (Lozap® Plus), according to its influence on circadian blood pressure profile (CBPP) in patients with arterial hypertension (AH). Material and methods. In 25 patients with Stage I-II AH, the influence of 8-week Lozap® monotherapy (n=12), 50 mg/d, and its fixed-dose combination with hydrochlorothiazide, Lozap® Plus (n=13), on CBPP was studied. Office BP (BPo) measurement, and 24-hour BP monitoring (BPM) were performed. Results. After 4 weeks of Lozap® monotherapy, BPo decreased by -8.4±10.7/-11.2±10.7 mm Hg (p<0.001); target BP level was reached in 48% of participants. By Week 8, BPo decreased by -13.0±9.0/-5.8±9.2 mm Hg (p<0.0001/0.01); target BP level was achieved in 92% of the patients. According to 24-hour BPM, daytime BP decreased by -22.3±12.1/13.8±11.2 mm Hg (р<0.0001), nighttime BP - by -25.9±16.7/16.4±11.3 mm Hg (р<0.0001). Daytime, nighttime, and 24-hour target BP levels were reached in 80%, 72%, and 88% of the participants, respectively. Т/Р ratio 71.6%/72.9% is an evidence of sufficient, even antihypertensive effect of Lozap® and Lozap® Plus. These medications significantly increased nighttime BP decline and normalized BP circadian rhythm (CP) in most patients. The therapy was well tolerated, with minimal adverse reactions, and side effects. Conclusion. Antihypertensive therapy with Lozap® and Lozap® Plus provides prolonged and even antihypertensive effect, corrects CBPP by reducing pressure workload, pulse BP, and improving BP CR. The maximal-dose therapy gives an opportunity to achieve target BP levels in 92% of the patients.https://cardiovascular.elpub.ru/jour/article/view/929артериальная гипертониялозартандженерикисуточное мониторирование артериального давления |
| spellingShingle | L. G. Ratova I. P. Kolos I. E. Chazova Angiotensin II receptor antagonists – we have moved closer to the patient Кардиоваскулярная терапия и профилактика артериальная гипертония лозартан дженерики суточное мониторирование артериального давления |
| title | Angiotensin II receptor antagonists – we have moved closer to the patient |
| title_full | Angiotensin II receptor antagonists – we have moved closer to the patient |
| title_fullStr | Angiotensin II receptor antagonists – we have moved closer to the patient |
| title_full_unstemmed | Angiotensin II receptor antagonists – we have moved closer to the patient |
| title_short | Angiotensin II receptor antagonists – we have moved closer to the patient |
| title_sort | angiotensin ii receptor antagonists we have moved closer to the patient |
| topic | артериальная гипертония лозартан дженерики суточное мониторирование артериального давления |
| url | https://cardiovascular.elpub.ru/jour/article/view/929 |
| work_keys_str_mv | AT lgratova angiotensiniireceptorantagonistswehavemovedclosertothepatient AT ipkolos angiotensiniireceptorantagonistswehavemovedclosertothepatient AT iechazova angiotensiniireceptorantagonistswehavemovedclosertothepatient |